Effects of the National Institute for Health and Clinical Excellence's technology appraisals on prescribing and net ingredient costs of drugs in the National Health Service in England

International Journal of Technology Assessment in Health Care

Volumn 25, Issue 3, 2009, Pages 262-271

  Dietrich, Eva Susanne ^a,b  

^a TK Scientific Institute for Benefit and Efficiency   (Germany)

^b Health Econ Ltd   (Switzerland)

Author keywords

Health technology assessment; IQWiG; NICE; Techniker Krankenkasse; Technology appraisals

Indexed keywords

DECREASING EFFECT; DEPARTMENT OF HEALTHS; ENGLAND; EVIDENCE-BASED MEDICINE; GERMANY; HEALTH TECHNOLOGY ASSESSMENTS; IQWIG; NATIONAL HEALTH SERVICES; ROLE MODEL; TECHNIKER;

COST REDUCTION; HEALTH; HEALTH CARE; REGRESSION ANALYSIS; STADIUMS; TECHNOLOGICAL FORECASTING; TECHNOLOGY;

COST BENEFIT ANALYSIS;

AMANTADINE; BETA INTERFERON; CARBAMAZEPINE; CELECOXIB; CLOPIDOGREL; ETIRACETAM; ETODOLAC; GABAPENTIN; GLATIRAMER; HUMAN GROWTH HORMONE; INSULIN GLARGINE; LAMOTRIGINE; MELOXICAM; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OSELTAMIVIR; OXCARBAZEPINE; PIOGLITAZONE; RIBAVIRIN; ROFECOXIB; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; ZALEPLON; ZANAMIVIR; ZOLPIDEM; ZOPICLONE; DRUG;

ACUTE CORONARY SYNDROME; AMBULATORY CARE; ARTICLE; COST EFFECTIVENESS ANALYSIS; DATA EXTRACTION; DRUG COST; EPILEPSY; EVIDENCE BASED MEDICINE; GERMANY; GROWTH HORMONE DEFICIENCY; HEALTH CARE; HEPATITIS C; INFLUENZA; INSOMNIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY GRAFT REJECTION; MODEL; MULTIPLE SCLEROSIS; NATIONAL HEALTH ORGANIZATION; NATIONAL HEALTH SERVICE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OSTEOARTHRITIS; PREDICTION; PRESCRIPTION; PUBLIC HEALTH SERVICE; PUBLICATION; REGRESSION ANALYSIS; REIMBURSEMENT; RHEUMATOID ARTHRITIS; TECHNOLOGY; UNITED KINGDOM; ADVISORY COMMITTEE; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST BENEFIT ANALYSIS; ECONOMICS; STANDARD;

ADVISORY COMMITTEES; COST-BENEFIT ANALYSIS; ENGLAND; PHARMACEUTICAL PREPARATIONS; STATE MEDICINE; TECHNOLOGY ASSESSMENT, BIOMEDICAL; WALES;

EID: 70350445247     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462309990110     Document Type: Article

References (21)

1. Abacus International; Howard S, Harrison L. NICE Guidance Implementation Tracking. Data Sources, Methodology & Results. 2005. http://www.nice.org.uk/ niceMedia/pdf/Abacus-report.pdf (accessed November 2, 2008).
2. Audit Commission. Managing the financial implications of NICE guidance. http://www.audit-commission.gov.uk/ SiteCollectionDocuments/ AuditCommissionReports/National Studies/ ManagingTheFinancialImplicationsOfNiceGuidance08 Sep05REP.pdf.
3. Bundesministerium für Gesundheit (German Department of Health). Gesetz zur Stärkung des Wettbewerbs in der Gesetzlichen Krankenversicherung (GKV-Wettbewerbsstärku ngsgesetz-GKV-WSG), Page 6-7, http://www.bmg.bund. de/ cln-041/nn-600124/DE/Gesetze-und-Verordnungen/zur-Gese tzlichen- Krankenversicherung/zur-gesetzlichen-krankenversic herung-node,param=.html--nnn= true (accessed 07 May 2007).
4. Department of Health. New statutory obligations for NHS to fund treatments recommended by NICE. Press release 2001/0599. http://www.dh.gov.uk/ en/Publicationsandstatistics/Press releases/DH-4011543 (accessed November 22, 2006).
5. Department of Health. Prescription costs analysis statistics. http://www.dh.gov.uk/PublicationsAndStatistics/Statistics/Stat isticalWorkAreas/StatisticalHealthCare/fs/en (accessedMay 7, 2007).
6. Duerden M, Miller J, Godmann B, Mallinson M, Sullivan N. Centralized guidance - how NICE and SIGN impact on care in the UK. In: Klusen N, Straub Ch, eds. Bausteine für ein neuesGesundheitswesen - Technik, Ethik,Ökonomie; 2003:51-61.
7. IGES Institut für Gesundheits-und Sozialforschung; Cassel D, Wille, E. Steuerung der Arzneimittelausgaben und Stärkung des Forschungsstandortes für die pharmazeutische Industrie. Gutachten für das Bundesministerium für Gesundheit. Berlin: Bundesministerium für Gesundheit, Referat Öffentlichkeitsarbeit; 2006.
8. NICE, National Institute for Health and Clinical Excellence. Home page. http://www.nice.org.uk (accessed November 2, 2008).
9. NICE, National Institute for Health and Clinical Excellence. NICE Annual Reports 2000-2005. http://www.nice.org.uk/ page.aspx?o=201896 (accessed May 7, 2007).
10. NICE, National Institute for Health and Clinical Excellence. Published technology appraisals. http://www.nice.org.uk/guid ance/index.jsp?d-16544-s= 2&d-16544-o=2&status=3&d-16 544-p=9&action=byType&type=6 (accessed November 28, 2008).
11. NICE, National Institute for Health and Clinical Excellence. NICE Annual Report 2005-2006. Available from: http://www. nice.org.uk/niceMedia/pdf/ boardmeeting/brdju106item2.pdf (accessed June 4, 2009).
12. Office of Fair Trading. The Pharmaceutical Price Regulation Scheme - An OFT market study. http://www.oft.gov.uk/shared-oft/reports/comp-policy/oft885. pdf (accessed December 18, 2008).
13. Raftery J. NICE: Faster access to modern treatments? Analysis of guidance on health technologies. BMJ. 2001;323:1300-1303.
14. Raftery J. Review of NICE's recommendations, 1999-2005. BMJ. 2006;332:1266-1271.
15. Rawlins MD. In pursuit of quality: The National Institute for Clinical Excellence. Lancet. 1999;353:1079-1082.
16. RawlinsMD. NICE and the public health. Br J Clin Pharmacol. 2004;58:575-580.
17. Rothgang H, Niebuhr D, Wasem J, Greß S. Das National Institute for Clinical Excellence (NICE) - Staatsmedizinisches Rationierungsinstrument oder Vorbild für die evidenzbasierte Bewertung medizinischer Leistungen? Gesundheitswesen. 2004;66:303-310.
18. Sheldon TA, Cullum N, Dawson D, et al. What's the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients' notes, and interviews. BMJ. 2004;329:999-1003.
19. Scriba P C, Middeke M. Was das IQWiG besser machen (können) sollte. Dtsch Med Wochenschr. 2007;137:137-138.
20. Waiß S. Das National Institute for Clinical Excellence. Lösungsansätze für die Qualitäts-und Effizienzdefizite im deutschen Gesundheitswesen? Sozialer Fortschritt. 2003;47-54.
21. Zentner A, Valesco-Garrido M, Busse R. Methoden zur vergleichenden Bewertung pharmazeutischer Produkte. Eine internationale Bestandsaufnahme zur Arzneimittelevaluation. DIMDI (eds.); 2005. http://gripsdb.dimdi.de/de/hta/hta- berichte/hta122-bericht-de.pdf (accessed November 2, 2008).